MultiStem Administration for Stroke Treatment and Enhanced Recovery Study
Lead PI: N/A
Status: Site Selection
No. of Patients Currently Recruited: 0 No. of Patients Required: 300 Globally
MASTERS-2 is a Phase III, double blind, randomised, placebo-controlled study designed to evaluate the efficacy of allogenic, regenerative therapy, MultiStem(R), on the functional outcome of patients with acute cortical ischaemic stroke. MultiStem is administered intravenously to patients within 36 hours of symptom onset.
MASTERS-1 Phase II Trial: